Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. There pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response
Recent Articles
- Transforming Digital Defense: Cyabra's New AI Insights Feature
- Housing Affordability: A Struggle for Singles Compared to Couples
- Global Baby Care Products Market Growth and Trends to Watch
- Xeris Biopharma Engages Investors at Upcoming Conferences
- Celebrating Excellence in Healthcare: Press Ganey's Honorees
- Illinois Tool Works Highlights Strong Financial Performance
- Innovative Wealth Management Solutions Introduced by DriveWealth and OneVest
- Streamlining Business Operations with Katana Cloud Inventory
- Oxbridge Re and SurancePlus Embrace Innovative Crypto Strategies
- MVNO Market Growth Projection Shows Promising Trends Ahead
- Oragenics, Inc. Highlights Groundbreaking Brain Health Initiatives
- Twin Disc Declares Latest Dividend, Reflecting Financial Strength
- Empower Unveils New Consumer-Directed Healthcare Solutions
- e-therapeutics Shares Groundbreaking Findings on ETX-148
- Crypto Philanthropy Surges Beyond $1 Billion in Giving Block's Report
- Asia Broadband Advances with Next-Gen AABB Wallet for Crypto
- Innovative Solutions to Tackle Financial Fraud in Businesses
- Uni-Fuels Strengthens Industry Ties with Key Sponsorship
- Smead International Value Fund: A Three-Year Investment Journey
- Ventyx Biosciences Set to Showcase Innovations at Key Conference
- Advancements in Aprea Therapeutics' Innovative Cancer Treatments
- Pitney Bowes Sends Security Standards Skyward with StateRAMP
- Exciting Grant Enhances Breast Cancer Care Initiatives
- Vertiv's Insights on Digital Infrastructure at Upcoming Events
- Upcoming Fourth Quarter Results Announcement for WillScot
- Markel Canada Elevates Leadership with New Underwriting Role
- Vaxcyte's VAX-31 Study for Pneumococcal Disease Hits Milestone
- UBS Advisor Teams Shine in Forbes Best-in-State Rankings
- UBS Recognizes 23 Top Wealth Management Teams in 2025 List
- Akoya Biosciences Expands Product Range to Enhance Research
- Indaptus Therapeutics Expands Decoy20 Trials in Canada
- Celebrating UBS Advisor Teams Recognized by Forbes 2025
- Transforming Claims Management with Wisedocs' Latest Innovations
- Cellectar Biosciences Highlights Innovative Cancer Therapies
- Celebrating Florida's Top UBS Advisor Teams Recognized in 2025
- Guidehouse Recognized for Excellence with Three KLAS Awards
- Chris Barton Sets the Stage for Innovation at Platform//2025
- ON24 Celebrates Trailblazers in Digital Engagement for 2024
- Blue Cross Blue Shield of Massachusetts Welcomes New Leadership
- Palella Holdings Broadens Portfolio with Strategic Acquisition
- Celebrating a Decade of Leadership in Nephrology Programs
- NRC Health Achieves Top Ranking in Healthcare Management Services
- Blueprint Medicines to Announce Financial Results and Updates
- Kirstie Settas-Jones Strengthens Alliant's Employee Benefits Team
- Lifesum Revolutionizes Nutrition with Smart Meal Tracking
- Transforming Talent Acquisition: SHL's Innovative Interview Solution
- Findhelp Earns Top Honors in Social Health Technology Again
- Plaza Tire Service Expands with New Location in Arkansas
- Join Autodesk's Upcoming Financial Results Conference Call
- Aethlon Medical's Q3 Financial Results Call Announcement